| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| R2 Technology, Inc. |
| 325 Distel Circle, Los Altos, CA 94022 * (650) 254-7200 |
| Business Description | The company develops, manufactures and sells proprietary medical systems to assist radiologists in the detection of cancer. Their computer-aided detection, or CAD, system analyzes medical images and identifies and marks suspicious image features. |
|
Filing Information Not yet | |||
| To Trade As | RTWO (NASNTL) | Industry | Manufacturing (SIC 3841) |
| Type of Stock Offered | Common Shares | Filing Date | 12/28/2001 |
| Domestic Shares Filed | 4,500,000 | Filing Range | $10.00 - $12.00 |
| Foreign Shares Filed | 0 | Offering Amount | $49,500,000 |
| Company Shares | 4,500,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1998 | 12/31/1999 | 12/31/2000 | 9/30/2000 | 9/30/2001 | ||
| Revenues | - | - | 0.172 | 1.894 | 4.932 | 3.351 | 18.174 |
| Income from Oper. | - | - | -10.777 | -10.416 | -14.277 | -8.747 | -8.475 |
| Net Income | - | - | -10.229 | -9.955 | -14.032 | -8.540 | -8.309 |
| E.P.S | - | - | -4.140 | -3.700 | -4.460 | -2.750 | -2.460 |
| Revenue Growth (%) | - | - | 1,001.16 | 160.401 | 442.35 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -9.38 | -5.91 | -8.38 | ||||
| Cash Flow - Inv. | 1.53 | 4.24 | 0.73 | ||||
| Cash Flow - Fin. | 19.39 | 0.20 | -3.07 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2001 | Financial Ratios | ||||
| Total Assets | 21.37 | Current Assets | 18.54 | Current Ratio | 1.42 |
| Total Liab. | 79.90 | Current Liab. | 13.03 | Debt Ratio | 373.88% |
| Total Equity | -58.53 | Working Cap. | 5.51 | Debt to Equity Ratio | - |
| Cash | 4.53 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes, including working capital, research and development, sales and marketing, clinical and regulatory studies, capital expenditures, and investments in and potential acquisitions of complementary businesses, products, and technologies. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Auditor | Deloitte & Touche |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Morgan Stanley Venture Partners III, L.P. and affiliates | 31.20 | |
| Alta V Limited Partnership and affiliates | 7.30 | |
| ARCH Venture Fund II, L.P. and affiliates | 7.00 | |
| Equity Asset Investment Trust | 6.70 | |
| Sigma Partners II, L.P. and affiliates | 6.10 | |
| Note: represents ownership of 5% or more prior to the offering. | ||